Key Takeaways
- Discovery Behavioral Health, one of the largest behavioral health platforms in the country and a Webster Equity Partners portfolio company, defaulted on $280 million in debt owed to Capital One and HPS Investment Partners under agreements originally struck in June 2021.
- The default was triggered by a dispute over how Discovery accounted for the expenses of shuttered facilities when calculating its debt-to-earnings ratio. Capital One argued the accounting adjustments made Discovery’s financial position look stronger than it was. A five-month negotiation nearly produced a resolution through the sale of Discovery’s outpatient division, Discovery Medical Services, but the deal collapsed on October 13, 2025.
- After the deal fell apart, events accelerated: the founding CEO retired and was replaced in November, Discovery filed emergency motions in December to block a lender takeover, a judge rejected those arguments the following day, and Discovery withdrew its legal challenge six days after filing. Capital One dismissed the board and installed its own. The new CEO, Tom Britton, appears to have been removed along with Discovery’s leadership.
- The residential-to-outpatient pivot at the core of Discovery’s strategy is not unusual across behavioral health, but the transition itself is expensive. Lease obligations, staff severance, and operational wind-down costs continue after facilities close. For a company carrying significant debt, these transition costs can strain the financial covenants designed to ensure stability.
- Commercial payers have historically resisted raising behavioral health reimbursement at rates that keep pace with rising labor, real estate, and compliance costs. Discovery’s then-CEO John Peloquin described the dynamic before his departure: payers were unwilling to supplement providers for inflationary pressures or rising interest rates. The resulting margin squeeze cannot be fully offset by operational efficiency.
- The SUD treatment market has been contracting relative to other behavioral health subsectors. Deal volume in SUD lagged autism and mental health throughout 2025. Medicaid redetermination, tightening eligibility, and the absence of successful recent exits have kept institutional buyers cautious.
- Webster Equity Partners holds three behavioral health portfolio companies with three distinct trajectories: InBloom Autism Services sold to Elysium Management for $75 million after a seven-year hold; Discovery was seized by its lenders; and BayMark Health Services, the largest addiction treatment provider in North America, is being marketed for sale while managing active litigation from a 2024 data breach.
Discovery Behavioral Health spent years building one of the largest behavioral health platforms in the country, operating residential and outpatient programs across multiple states with backing from Webster Equity Partners. By late 2025, the company’s lenders had taken control.
The unraveling centered on $280 million in debt that Discovery owed to Capital One and its financial partner, HPS Investment Partners, under agreements originally struck in June 2021. Discovery had been pivoting from residential care toward outpatient services under then-CEO John Peloquin, a strategic shift that required closing dozens of facilities. The closures carried their own costs: rent obligations on vacated properties, ongoing utility expenses, and the operational drag of unwinding long-term commitments. The debt agreements had already been amended multiple times to accommodate missed covenants, each amendment buying time but not resolving the underlying strain.
The dispute that brought things to a head was technical but consequential. It came down to how Discovery accounted for the expenses of its shuttered facilities when calculating its debt-to-earnings ratio. Capital One argued that Discovery’s accounting adjustments had the effect of making the company’s financial position look stronger than it was, and that without those adjustments, Discovery would have tripped its covenants outright. In May 2025, Capital One sent a formal notice of potential default.
What followed was a five-month negotiation that nearly produced a resolution. Webster agreed to sell Discovery’s outpatient division, Discovery Medical Services, and use the proceeds to settle the dispute. Capital One began documenting the agreement in an amendment to the credit facility. Then, on October 13, Capital One learned that Discovery and its sponsor were no longer consummating the sale or executing the amendment. The deal that would have kept the company intact had collapsed.
Events moved quickly after that. In November, Peloquin retired and was replaced as CEO by Tom Britton, a behavioral health executive who had previously led Gateway Foundation, American Addiction Centers, and Accanto Health. Weeks later, on December 15, Discovery filed emergency motions in New York state court seeking to block a takeover. The judge rejected Discovery’s arguments at the sole hearing the following day, declining to impose any restraint beyond preventing a “fire sale” of assets. Six days after filing, Discovery withdrew its legal challenge. Capital One dismissed the board and installed its own. Britton, who had been CEO for barely a month, appears to have been removed along with the rest of Discovery’s leadership.
The Residential-to-Outpatient Transition That Discovery’s Leveraged Balance Sheet Couldn’t Absorb
Discovery’s strategic pivot from residential to outpatient care was not unusual. Across behavioral health, providers have been shifting toward outpatient and community-based models for years, driven by payer preferences, regulatory trends, and the simple economics of facility-based care. Residential programs require real estate, round-the-clock staffing, and the kind of fixed overhead that becomes painful when census dips. Outpatient programs, by contrast, are lighter on capital, more flexible in staffing, and increasingly favored by insurers who see them as cost-effective alternatives to inpatient stays.
The challenge is that the transition itself is expensive. Closing a residential facility does not immediately eliminate its costs. Lease obligations continue. Staff severance comes due. The administrative work of unwinding contracts, reassigning patients, and satisfying regulatory requirements generates its own expenses. For a company carrying significant debt, these transition costs can compound in ways that strain the very financial covenants designed to ensure stability. Discovery’s experience illustrates how a strategically sound decision, moving toward a lower-cost, higher-margin care model, can create short-term financial pressure that overwhelms a leveraged balance sheet.
The broader behavioral health industry has been navigating this transition unevenly. Some companies have managed it by running residential and outpatient programs in parallel, gradually shifting the mix as outpatient capacity ramps up. Others have attempted faster conversions, betting that the short-term pain will be offset by improved unit economics on the other side. The companies that struggle tend to be those carrying the most debt, where the margin for execution error is thinnest.
Why Commercial Insurance Reimbursement Makes Behavioral Health at Scale Financially Precarious
What makes behavioral health particularly challenging to scale under leverage is the gap between what care costs and what the billing system actually pays.
Discovery’s revenue was largely generated through commercial insurance plans. But commercial payers have historically resisted raising behavioral health reimbursement beyond traditional single-digit percentage increases, even as labor costs, real estate, and compliance expenses climbed at rates well above that threshold. Peloquin himself described the dynamic before his departure: payers were unwilling to supplement providers for inflationary pressures or rising interest rates. The result was a margin squeeze that no amount of operational efficiency could fully offset.
The problem compounds for providers treating patients with co-occurring conditions, which describes the majority of people in behavioral health treatment. Mental health services and substance use disorder treatment often require separate billing streams, different prior authorization processes, and distinct documentation requirements, even when the same clinician addresses both in the same session. For a diversified platform like Discovery, which treated eating disorders, mental health conditions, and substance use across residential and outpatient settings, this fragmentation created friction at every level: billing teams navigating different coding taxonomies, clinical staff documenting to satisfy regulators whose frameworks did not reflect the patients in front of them, and revenue that consistently lagged behind the cost of delivering care. For PE-backed platforms that depend on predictable cash flows to service debt, this is not an abstract policy problem. It is the operating environment.
The SUD Treatment Market’s Quiet Contraction and Why Buyer Interest Has Shifted Elsewhere
Discovery’s troubles unfolded against a backdrop of broader difficulty in the substance use disorder treatment market. While autism and mental health services have seen strong M&A activity, the SUD sector has moved in the opposite direction. Deal volume in SUD lagged behind other behavioral health subsectors throughout 2025. M&A advisors have described an environment where buyers are “distracted” by opportunities in autism and mental health, where there are fewer regulatory unknowns and more predictable reimbursement dynamics.
The SUD market faces its own set of headwinds. Medicaid redetermination, which resumed after pandemic-era continuous enrollment provisions expired, has created uncertainty around patient eligibility. The prospect of tighter eligibility requirements raises the possibility of cash flow disruptions for providers that rely heavily on Medicaid reimbursement. Companies that were once among the most acquisitive buyers in the SUD space have gone quiet, and industry advisors note that successful exits are needed before other PE firms will feel comfortable re-entering the segment.
For Discovery, which operated SUD treatment programs alongside its mental health and residential services, these market-level dynamics compounded the company-specific challenges. A company pivoting its care model while carrying heavy debt, in a subsector where buyer interest and reimbursement certainty were both declining, faced pressure from multiple directions simultaneously.
Webster Equity Partners’ Three Portfolio Companies: Three Very Different Outcomes
Discovery is not the only Webster Equity Partners portfolio company to have had a complicated outcome in recent years. Webster acquired InBloom Autism Services in 2018 and held it for seven years before selling it to Elysium Management for $75 million near the end of 2025. That seven-year hold period ran well past the typical PE window, a timeline likely shaped by pandemic disruption and the broader deal-volume slowdown that compressed behavioral health M&A activity from 2021 onward.
Webster’s investment in InBloom came during what a January 2026 JAMA Pediatrics study would later document as the peak years of PE expansion into autism services, when private equity firms acquired nearly 600 service delivery sites across 42 states. The same institutional appetite for behavioral health that drew PE capital into autism also drove investments in substance use disorder treatment and residential mental health, the sectors where Discovery operated. The difference was in the underlying economics: autism’s outpatient model and relatively straightforward billing offered more predictable cash flows than the facility-heavy, operationally complex business that Discovery was running, where commercial payers resisted rate increases even as the cost of residential care climbed.
Webster is also currently attempting, for the second time, to sell BayMark Health Services, the largest addiction treatment provider in North America. Webster first explored a sale of BayMark in 2019, then moved the company to a continuation vehicle in 2021. Axios reports that BayMark’s marketed EBITDA now sits at approximately $75 million. BayMark also faces ongoing litigation from a data breach that occurred in late 2024 and was disclosed in early 2025.
Three portfolio companies, three distinct trajectories: one sold at a modest multiple after an extended hold, one seized by its lenders after a debt default, and one being marketed for sale while managing active litigation.
What Discovery Behavioral Health’s Default Reveals About Leveraged Behavioral Health Platforms
The behavioral health industry in 2026 is a study in unevenness. Autism services are seeing record deal volumes and strong multiples. Mental health platforms are attracting buyer interest. And the SUD market, where Discovery operated some of its largest programs, is contracting.
Within that landscape, the companies that are thriving tend to share a few characteristics: manageable leverage, diversified payer mixes, operational infrastructure that can absorb the complexity of behavioral health billing, and enough geographic diversification to avoid overexposure to any single state’s Medicaid policies. The companies that are struggling tend to be those where one or more of those factors is missing, and where the debt load leaves no room for the kind of operational turbulence that behavioral health, with its regulatory complexity and reimbursement unpredictability, routinely produces.
Discovery’s default was not an isolated event. It was a concentrated expression of pressures that exist, in varying degrees, across the behavioral health sector. The residential-to-outpatient transition. The reimbursement gap between what care costs and what payers will pay. The contraction of the SUD market. The strain of servicing debt in a business where revenue is inherently lumpy and regulatory exposure is high. Any one of these challenges is manageable in isolation. Together, and under enough leverage, they can be overwhelming.
Frequently Asked Questions
What happened to Discovery Behavioral Health?
Discovery Behavioral Health, a Webster Equity Partners-backed behavioral health platform operating residential and outpatient programs across multiple states, defaulted on $280 million in debt owed to Capital One and HPS Investment Partners. The default followed a dispute over how Discovery accounted for costs from shuttered residential facilities when calculating its debt covenant compliance ratios. A five-month negotiation that nearly produced a resolution through the sale of Discovery’s outpatient division, Discovery Medical Services, collapsed on October 13, 2025, when Discovery and Webster declined to proceed. In December 2025, Discovery filed emergency motions in New York state court seeking to block a lender takeover; the judge rejected its arguments the following day. Discovery withdrew its legal challenge six days later. Capital One subsequently dismissed the board and installed its own.
Why did Discovery Behavioral Health’s residential-to-outpatient pivot create financial problems?
The pivot was strategically defensible: outpatient behavioral health programs carry lower fixed costs, more flexible staffing requirements, and growing payer support compared to residential facilities. But closing residential facilities does not immediately eliminate their costs. Lease obligations continue running after operations cease. Staff severance is due. The administrative work of unwinding patient transfers, regulatory compliance, and vendor contracts generates its own expenses. For Discovery, which was simultaneously carrying $280 million in debt subject to covenant requirements, the transition costs created short-term financial pressure that compounded on a balance sheet with little margin for error. The debt covenants were amended multiple times before the situation reached a breaking point, each amendment providing time but not resolving the underlying structural strain.
Why is behavioral health difficult to scale under significant debt?
Two structural features of behavioral health make leveraged scaling particularly challenging. First, commercial payers have historically resisted raising behavioral health reimbursement at rates that keep pace with labor, real estate, and compliance cost inflation, creating a persistent margin squeeze that no amount of operational efficiency can fully close. Second, the behavioral health billing environment is inherently fragmented: patients with co-occurring conditions, who represent the majority of people in treatment, often require separate billing streams, prior authorization processes, and documentation requirements for mental health and substance use services even when delivered by the same clinician in the same session. For a PE-backed platform depending on predictable cash flows to service debt, this fragmentation creates revenue that consistently lags behind the cost of delivering care, and that gap becomes unsustainable when the debt load is heavy enough.
What is the current state of the SUD treatment M&A market?
The SUD treatment M&A market contracted meaningfully relative to other behavioral health subsectors in 2025. M&A advisors have described a buyer environment where investor attention has shifted toward autism services and mental health platforms, which offer more predictable reimbursement dynamics and fewer regulatory unknowns than substance use disorder treatment. Several headwinds are specific to SUD: Medicaid redetermination has introduced patient eligibility uncertainty for providers with heavy Medicaid dependence; the absence of high-profile successful exits has kept institutional buyers cautious; and the out-of-network, residential-heavy business model that once attracted PE interest has faced increasing scrutiny from commercial payers. The companies that were once the most acquisitive buyers in the SUD space have largely gone quiet, and advisors note that a few successful exits will likely be needed before capital returns to the segment in volume.
What does the Webster Equity Partners portfolio reveal about PE investment in behavioral health?
Webster’s three current behavioral health holdings illustrate the range of outcomes that PE investment in the sector produces. InBloom Autism Services was held for seven years before a sale at $75 million to Elysium Management, a hold period well beyond the typical three-to-five year PE window, likely shaped by pandemic disruption and deal-market compression. Discovery Behavioral Health defaulted on its debt and was seized by lenders. BayMark Health Services, the largest addiction treatment provider in North America, is being marketed for sale for the second time while managing litigation from a 2024 data breach. The divergence across three companies in the same portfolio reflects what a growing body of research on PE in behavioral health has documented: outcomes vary widely by subsector, business model, and the specific operating environment at the time of investment. Autism services offered more predictable unit economics than the facility-heavy, commercially reimbursed residential behavioral health business that Discovery was running, and the results reflect that difference.
What does the Discovery Behavioral Health default mean for the broader behavioral health industry?
Discovery’s default is instructive as a concentrated expression of pressures that exist, in varying degrees, across the behavioral health sector. The residential-to-outpatient transition is underway industry-wide, and the transition costs are real for any company navigating it under leverage. The commercial reimbursement gap between what behavioral health care costs and what payers will pay is structural and persistent. The SUD market is contracting relative to other behavioral health subsectors, compressing buyer interest and exit options for companies with SUD exposure. And the regulatory complexity of behavioral health billing, particularly for diversified platforms treating multiple conditions, creates revenue unpredictability that becomes dangerous when the debt load is high. The companies navigating these pressures successfully tend to share manageable leverage, diversified payer mixes, and sufficient operating reserves to absorb regulatory or market turbulence without triggering covenant violations. Discovery had none of those buffers when the challenges converged.
